Want to see HK:1801 full AI Analyst Report?
Top Page
Innovent Biologics
(1801)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$85.00
▼(-15.08% Downside)
Action:Downgraded
Date:08/27/26
The score is driven primarily by improved financial performance in 2025 (profitability and especially cash flow strength) and a conservative balance sheet, partially offset by an uneven multi-year track record. Technically the stock has strong momentum versus moving averages, but elevated RSI suggests near-term stretch. The biggest drag is valuation, with a very high P/E that raises expectation risk.
Positive Factors
Revenue and Profit Inflection
The 2025 improvement shows stronger commercial scale and a meaningful move toward profitability. If revenue growth and positive earnings persist, Innovent can fund development internally, strengthen its market position, and improve operating leverage across its biologics portfolio.
Negative Factors
Unproven Profitability Durability
The return to profit is encouraging, but the preceding multi-year period of operating losses shows that earnings durability has not yet been established. Continued execution will be necessary to demonstrate that the 2025 improvement reflects a lasting business model shift.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profit Inflection
The 2025 improvement shows stronger commercial scale and a meaningful move toward profitability. If revenue growth and positive earnings persist, Innovent can fund development internally, strengthen its market position, and improve operating leverage across its biologics portfolio.
Read all positive factors
Innovent Biologics (1801) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$139.32B
Dividend YieldN/A
Average Volume (3M)10.20M
Price to Earnings (P/E)95.6
Beta (1Y)0.72
Revenue Growth42.64%
EPS Growth9.67%
CountryHK
Employees8,754
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.71
Shares Outstanding1,746,918,300
10 Day Avg. Volume11,660,088
30 Day Avg. Volume10,200,292
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)6.12
Price to Sales (P/S)9.09
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$135.57Price Target Upside35.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)1.37
Revenue Forecast (FY)HK$18.71B
Innovent Biologics Business Overview & Revenue Model
Company Description
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encomp...
How the Company Makes Money
Innovent primarily makes money by selling its commercialized prescription biologic drugs, generating product sales revenue through distribution to hospitals and pharmacies (typically supported by a field sales organization and channels appropriate...
Innovent Biologics Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
76
Positive
Cash Flow
73
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.59B | 13.04B | 9.42B | 6.21B | 4.56B | 4.27B |
| Gross Profit | 12.62B | 10.00B | 7.91B | 4.40B | 3.63B | 3.70B |
| EBITDA | 2.54B | 1.33B | -336.10M | -660.68M | -1.75B | -2.37B |
| Net Income | 1.22B | 813.57M | -94.63M | -1.03B | -2.18B | -2.73B |
Balance Sheet | ||||||
| Total Assets | 41.61B | 37.36B | 21.60B | 20.63B | 17.59B | 16.24B |
| Cash, Cash Equivalents and Short-Term Investments | 20.00B | 18.24B | 7.88B | 10.97B | 9.17B | 9.02B |
| Total Debt | 2.32B | 2.82B | 2.83B | 3.62B | 3.23B | 2.50B |
| Total Liabilities | 20.87B | 17.20B | 8.48B | 8.10B | 6.86B | 5.91B |
| Stockholders Equity | 20.74B | 19.36B | 13.12B | 12.53B | 10.73B | 10.33B |
Cash Flow | ||||||
| Free Cash Flow | 13.00B | 9.32B | -418.39M | -1.24B | -3.30B | -3.87B |
| Operating Cash Flow | 13.40B | 10.00B | 1.29B | 147.81M | -1.92B | -2.02B |
| Investing Cash Flow | -16.14B | -6.51B | -1.17B | -998.66M | -1.44B | -2.70B |
| Financing Cash Flow | 3.60B | 4.73B | -606.63M | 2.59B | 2.89B | 5.00B |
Innovent Biologics Technical Analysis
Negative
100.10
Price Trends
95.54
Negative
91.10
Negative
87.89
Negative
Market Momentum
-4.33
Positive
29.91
Positive
9.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1801, the sentiment is Negative. The current price of 100.1 is above the 20-day moving average (MA) of 88.60, above the 50-day MA of 95.54, and above the 200-day MA of 87.89, indicating a bearish trend. The MACD of -4.33 indicates Positive momentum. The RSI at 29.91 is Positive, neither overbought nor oversold. The STOCH value of 9.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1801.
Innovent Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$34.37B | 3.46 | 30.16% | 1.85% | 101.73% | 249.15% | |
66 Neutral | HK$51.82B | 7.90 | 105.60% | ― | 292.84% | ― | |
63 Neutral | HK$139.32B | 95.59 | 6.06% | ― | 42.64% | 9.67% | |
60 Neutral | HK$26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$76.70B | -66.50 | -10.86% | ― | 42.47% | -15.80% | |
41 Neutral | HK$30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
HK:1801
Innovent Biologics
79.75
-7.25
-8.33%
HK:1530
3SBio
13.54
-16.81
-55.39%
HK:9926
Akeso, Inc.
81.50
-31.90
-28.13%
HK:9995
RemeGen Co. Ltd. Class H
64.85
-25.15
-27.94%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.26
-11.32
-42.59%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
49.06
-20.79
-29.76%
Innovent Biologics Corporate Events
Innovent Biologics Posts Strong Q3 Revenue Growth as Global Expansion Strategy Accelerates
Oct 28, 2026
Innovent Biologics reported that product revenue exceeded RMB4.7 billion in the third quarter of 2026, representing year-over-year growth of more than 40 percent and underscoring the strength of its “dual-engine” strategy. Rapid market...
Innovent Wins China Approval for Jaypirca in All Lines of CLL/SLL Therapy
Sep 28, 2026
Innovent Biologics announced that China’s National Medical Products Administration has approved Jaypirca (pirtobrutinib) as a monotherapy for adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma across all lines of...
Innovent Biologics Grants Share Options and Restricted Shares Under 2024 Scheme
Sep 1, 2026
Innovent Biologics has granted 59,757 share options to nine grantees and 583,731 restricted shares to 63 grantees under its 2024 Share Scheme, subject to acceptance. The options, priced at HK$105.76 per share with a 10-year exercise period, largel...
Innovent Biologics Details Board and Committee Structure
Sep 1, 2026
Innovent Biologics, Inc. announced the current composition of its board of directors, detailing roles of executive, non-executive and independent non-executive members. The company also outlined the structure of its four board committees—Aud...
Innovent Biologics Reshapes Board Roles as Veteran Executive Retires from Full-Time Post
Aug 25, 2026
Innovent Biologics announced that long-serving executive director Ronald Hao Xi Ede will be re-designated as a non-executive director effective September 1, 2026, as he retires from full-time employment to focus on his family. Ede, a former chief ...
Innovent Biologics Delivers Strong First-Half 2026 Profit and Revenue Surge
Aug 25, 2026
Innovent Biologics reported a sharp rise in interim results for the six months ended 30 June 2026, with total revenue climbing 44.8% year on year to RMB8.62 billion and product revenue surging 56.7% to RMB8.20 billion. The company said the perform...
Innovent Biologics Sets Board Meeting to Approve 2026 Interim Results
Aug 10, 2026
Innovent Biologics, Inc. has scheduled a board meeting for August 25, 2026, to review and approve the interim results for the six months ended June 30, 2026. The company also plans to authorize the publication of these interim results, a key step ...
Innovent Biologics Posts Strong H1 2026 Revenue and Deepens Oncology, Global Expansion
Aug 5, 2026
Innovent Biologics reported total product revenue of over RMB8.2 billion for the first half of 2026, up more than 55% year-on-year, with second-quarter revenue exceeding RMB4.3 billion and growing about 60%. The strong performance was driven by it...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.